Leah Lawrence

Diagnostic magnetic resonance imaging strategies for the diagnosis of prostate cancer should be considered prior to biopsy of suspicious lesions, according to a recent study.

Participants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.

Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy (MDT), according to results of the screening phase of the phase II STOMP randomized trial.

Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.

A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.

A definitive radiotherapy dose for localized prostate cancer can be safely administered using high-dose rate brachytherapy as a single outpatient procedure.

Mood and adjustment disorders were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with prostate and breast cancer, according to a recent study.

Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.

Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.